Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options.
Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options.
Europeiska läkemedelsmyndighetens vetenskapliga kommitté för humanläkemedel (CHMP) har gett ett positivt yttrande kring Rezurock (belumosudil) och rekommenderar ett villkorat marknadsgodkännande i EU.